Abstract Submission
Abstract Submission Guidelines
ABSTRACT SUBMISSION GUIDELINES – The Joint Meeting of the International Cancer Imaging Society (ICIS) and the Oman Radiology and Molecular Imaging Society (ORMIS)
You are invited to submit an abstract for ICIS/ORMIS Conference, to be held on 30-31th January 2026, at the Grand Hyatt Muscat Hotel, Muscat Oman.
TO SUBMIT AN ABSTRACT, PLEASE READ ALL OF THE INSTRUCTIONS BELOW:
ABSTRACT SUBMISSION DEADLINE: 15 January 2026 – 11:59 PM.
NOTIFICATION ON ACCEPTANCE/REJECTION: 20 January 2026 – 11:59 PM.
Please note that only electronic submissions are accepted.
Abstract Topics for Submission:
- Brain Tumors
- Head and Neck Tumors
- Lung Cancer Imaging
- Break and Networking
- BI-RADS - Gallium 68 Applications in Oncology
- HCC/LI-RADS
- Biliary Tract Tumors
- Metastatic Liver Disease
- Pancreatic Cancer
- Staging Gastric Ca
- Rectal Cancer Staging and Restaging
- Renal Neoplasm
- PI-RADS
- O-RADS
- Ovarian Cancer-Epithelial Tumors
- Uterine/Cervical Cancer
- Whole-Body MRI
- Retroperitoneal Masses
Language
All abstracts must be submitted in English using the online submission form on the Joint Meeting of the International Cancer Imaging Society (ICIS) and the Oman Radiology and Molecular Imaging Society (ORMIS), website.
General Conditions
- Can be any topic related to the conference tracks or the above listed topic
- Abstracts are required for all presentations.
- Abstracts must be submitted maximum by 15 January 2026 – 23:59 GMT).
- All accepted Abstract presenter(s) will receive free registration to the conference to present your abstract at the conference.
- Abstracts submitted will be accepted only as Poster Abstracts.
- If selected, it is the responsibility of the presenter to bear his travel and accommodation expenses.
- The co-authors of the abstracts should register to the conference if you wish to receive the abstract poster certificate.
- Abstracts should clearly state: Background and aims, Methods, Results, Conclusions
- Use generic names of drugs. The presentation must be balanced and contain no commercial promotional content.
- Submissions may not contain patient names, hospital ID numbers or other identifying information.
- Please ensure that the email addresses of both the submitter and presenting author are accurate, as they will be used for all communication following the review process.
Please verify that your email address (submitter and presenting author) is correct as it will be used for contacting you after the review process.
Disclosure: Abstract submitter and presenter are required to disclose any conflict of interest.
Ensure that all co-authors approve the abstract submission, publication, and potential presentation.
Abstract submitters must consent to the Policies of Abstract Submission.